On June 10, Zai Lab rose 5.57% in regular trading, trading at HK$13.31/share, with trading volume of HK$178 million. The stock rallied on dual product milestones that boosted market sentiment.

On the news front, the company's first neuroscience product, xanomeline-trospium chloride capsules (KarXT), was officially shipped on June 9. The drug is now available in over 30 cities and nearly 50 hospitals nationwide, with the first prescription issued at Beijing Anding Hospital affiliated with Capital Medical University, targeting schizophrenia patients.

Additionally, China's National Medical Products Administration approved the marketing application for Tivdak (tisotumab vedotin for injection), indicated for adult patients with recurrent or metastatic cervical cancer who progressed during or after prior chemotherapy. The approval was based on statistically significant overall survival benefits demonstrated in the global Phase 3 innovaTV 301 clinical trial.

The simultaneous commercial launch of a neuroscience asset and regulatory approval of an oncology product represent meaningful pipeline catalysts, expanding Zai Lab's marketed portfolio and potential revenue base.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)